Revvity (NYSE:RVTY) Stock Jumps 5.2% – Here’s What Happened

Revvity Inc. (NYSE:RVTY) shares rose 5.2% on Thursday. The stock traded as high as $148.53 and last traded at $149.4930. Approximately 1,039,798 shares changed hands during trading, a decline of 29% from the average daily volume of 1,467,490 shares. The stock had previously closed at $142.11.

More Revvity News

Here are the key news stories impacting Revvity this week:

• Positive Sentiment: Revvity launched a CE-IVDR-certified automated screening kit in Europe to detect type 1 diabetes risk in children. The product expands the company’s GSP platform beyond newborn screening and could broaden its diagnostics revenue opportunity. RVTY Launches New Kit in Europe for Newborn Type 1 Diabetes Detection
• Positive Sentiment: The diabetes-test launch has attracted favorable market attention and helped push Revvity shares toward a new one-year high, reinforcing momentum in the stock. Revvity Hits New 1-Year High
• Neutral Sentiment: Revvity recently exceeded quarterly EPS and revenue expectations, reporting $1.41 EPS versus a $1.21 consensus estimate and $729.7 million in revenue versus $703.0 million expected. However, revenue declined 1.3% year over year, and fiscal 2026 EPS guidance remains $5.30-$5.40.
• Neutral Sentiment: Analysts maintain a consensus “Hold” rating, with a reported average price target of $116.57, below the current trading range. UBS and RBC also initiated coverage with neutral or sector-perform ratings.
• Negative Sentiment: Insider Maxwell Krakowiak sold 1,631 shares worth approximately $235,700, reducing his direct ownership by nearly 10%. The sale is relatively small but may add a modest cautionary signal after the recent rally. Revvity Insider Sells 1,631 Shares

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. Sanford C. Bernstein started coverage on Revvity in a report on Friday, June 26th. They issued a “market perform” rating and a $115.00 price objective for the company. Evercore reaffirmed an “outperform” rating on shares of Revvity in a report on Wednesday, August 5th. KeyCorp upped their target price on shares of Revvity from $125.00 to $165.00 and gave the stock an “overweight” rating in a report on Friday, September 4th. Wall Street Zen cut shares of Revvity from a “buy” rating to a “hold” rating in a report on Sunday, August 16th. Finally, UBS Group began coverage on Revvity in a research report on Wednesday, September 9th. They set a “neutral” rating and a $140.00 price target for the company. Four equities research analysts have rated the stock with a Buy rating and fourteen have given a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $116.57.

Revvity Price Performance

The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.50 and a current ratio of 1.80. The stock has a market cap of $16.83 billion, a P/E ratio of 71.83, a price-to-earnings-growth ratio of 2.74 and a beta of 1.09. The firm has a 50-day moving average price of $124.13 and a 200-day moving average price of $106.49.

Revvity (NYSE:RVTY) last announced its earnings results on Tuesday, August 4th. The company reported $1.41 earnings per share for the quarter, beating analysts’ consensus estimates of $1.21 by $0.20. Revvity had a net margin of 8.16% and a return on equity of 8.34%. The business had revenue of $729.69 million during the quarter, compared to the consensus estimate of $702.96 million. During the same quarter last year, the firm earned $1.18 earnings per share. The business’s revenue for the quarter was down 1.3% on a year-over-year basis. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS. On average, analysts forecast that Revvity Inc. will post 5.36 earnings per share for the current fiscal year.

Revvity Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, November 13th. Stockholders of record on Friday, October 23rd will be issued a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a dividend yield of 0.2%. The ex-dividend date of this dividend is Friday, October 23rd. Revvity’s payout ratio is presently 13.33%.

Insiders Place Their Bets

In other Revvity news, insider Tajinder Vohra sold 7,330 shares of the business’s stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $140.88, for a total transaction of $1,032,650.40. Following the completion of the sale, the insider directly owned 6,635 shares in the company, valued at $934,738.80. The trade was a 52.49% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Maxwell Krakowiak sold 1,631 shares of the stock in a transaction that occurred on Monday, September 21st. The stock was sold at an average price of $144.53, for a total transaction of $235,728.43. Following the completion of the transaction, the insider owned 14,781 shares in the company, valued at $2,136,297.93. The trade was a 9.94% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 9,046 shares of company stock valued at $1,277,685. 0.85% of the stock is owned by company insiders.

Hedge Funds Weigh In On Revvity

A number of hedge funds have recently made changes to their positions in the business. QRG Capital Management Inc. grew its stake in Revvity by 14.4% during the second quarter. QRG Capital Management Inc. now owns 5,881 shares of the company’s stock valued at $654,000 after acquiring an additional 742 shares in the last quarter. State Street Corp raised its stake in Revvity by 0.8% during the second quarter. State Street Corp now owns 4,342,739 shares of the company’s stock valued at $483,173,000 after purchasing an additional 32,426 shares in the last quarter. The Manufacturers Life Insurance Company increased its holdings in shares of Revvity by 5.8% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 368,938 shares of the company’s stock worth $41,048,000 after buying an additional 20,278 shares during the last quarter. Integrated Wealth Concepts LLC bought a new position in shares of Revvity in the 2nd quarter valued at about $171,000. Finally, Nykredit A S purchased a new stake in Revvity during the second quarter valued at approximately $358,000. Institutional investors own 86.65% of the company’s stock.

Revvity Company Profile

Revvity, Inc is a life sciences and diagnostics company that provides technologies, products and services used by researchers, healthcare professionals and laboratories. Its offerings support applications across genomics, proteomics, cellular analysis, drug discovery, disease research and laboratory testing.

The company develops and supplies scientific instruments, reagents, consumables, software and workflow solutions. Its portfolio includes platforms for genetic and molecular analysis, imaging, high-throughput screening, biomarker research and single-cell analysis, as well as laboratory solutions used in areas such as reproductive health and newborn screening.

Revvity was established in 2023 following the separation of PerkinElmer’s Applied, Food and Enterprise Services businesses from its Precision Diagnostics operations.